Quick answer
How did tesamorelin come to exist? It follows from a chain of discoveries: growth hormone-releasing factor was isolated and sequenced from a human pancreatic tumor in 1982, native GHRH was shown to be rapidly cleaved by dipeptidyl peptidase IV, the pituitary GHRH receptor was cloned in 1992, and chemists then protected the N-terminus of the full 44-residue sequence with a trans-3-hexenoyl group. The V8 product is a 10 mg lyophilized vial of that analog, ≥98% HPLC purity, with formula C221H366N72O67S. For laboratory research use only; not for human consumption.
Most peptide histories are told as product histories. This one is told as a problem history, because tesamorelin makes sense only when you know what problem it was built to solve. A hypothalamic hormone had been inferred for decades but could not be isolated; once it was, it proved too short-lived to study easily; and the response to that instability was a small chemical change that tells you a good deal about how peptide analogs are designed. The compound is supplied for laboratory research use only.
Timeline at a glance
| Year | Event | Source |
|---|---|---|
| 1982 | GH-releasing factor isolated from a human pancreatic tumor associated with acromegaly | Guillemin and colleagues, Science |
| 1982 | Characterization of the factor, a 44-residue peptide | Rivier and colleagues, Nature |
| 1982 | Sequence analysis of the tumor-derived factor | Spiess and colleagues, Biochemistry |
| 1989 | Enzymatic degradation of human GHRH by dipeptidyl peptidase IV and trypsin-like activity | Frohman and colleagues, J Clin Invest |
| 1990 | Structure, gene expression and heterogeneity of GHRH reviewed | Frohman and colleagues, Acta Paediatr |
| 1992 | Cloning and expression of the pituitary GHRH receptor | Mayo, Mol Endocrinol |
| 2011 | Review of tesamorelin as a stabilized GHRH analog in clinical development | Dhillon, Drugs |
The problem: a hormone that could be inferred but not found
The idea that the hypothalamus releases a factor that drives pituitary GH secretion was old, but a hypothalamic extract is a poor starting material: the factor is present in tiny amounts among many similar peptides. The break came from an unusual source. Acromegaly caused by pancreatic tumors had been described, and such tumors proved to be a rich source of the missing releasing factor. Guillemin and colleagues reported a growth hormone-releasing factor from one such tumor (Guillemin and colleagues, 1982). In the same year Rivier and colleagues characterized a factor from a human pancreatic islet tumor in Nature, and Spiess and colleagues published its sequence analysis in Biochemistry. The molecule they described is the 44-residue GHRH, with an amidated C-terminus.
That native sequence is the scaffold on which every later analog was built. The notation GHRH(1-44) refers to those 44 amino acids numbered from the N-terminus. Shorter N-terminal fragments retain receptor activity, which is why analogs of different lengths exist; the shorter fragment sermorelin is discussed in the sermorelin research overview.
The second problem: rapid inactivation
A natural peptide hormone can be perfectly designed for its job and still make a poor laboratory reagent. GHRH is cleared quickly. Frohman and colleagues examined its enzymatic degradation and identified dipeptidyl peptidase IV, together with trypsin-like activity, as responsible for breaking it down (Frohman and colleagues, 1989). Dipeptidyl peptidase IV removes the first two residues from the N-terminus of peptides that carry alanine or proline in the second position. Native GHRH starts Tyr-Ala, so it is a substrate. Removing those two residues leaves a peptide that no longer activates the receptor effectively.
For anyone running a long incubation, the practical consequence is clear: the amount of active ligand in the well falls over the course of the experiment, and the shape of the response curve reflects both receptor pharmacology and enzymatic loss. An analog resistant to that cleavage separates the two.
The receptor arrives
For a decade, the receptor itself was only known by what it did. Mayo reported the molecular cloning and expression of a pituitary-specific receptor for GHRH in 1992. The receptor is a class B G protein-coupled receptor that signals through cyclic AMP. Cloned receptor meant that analogs could be tested cleanly in cells that express only that receptor, giving the field a way to compare potency without the confounding of intact pituitary tissue. The same period saw GHRH biology summarized in reviews of its gene structure and molecular heterogeneity (Frohman and colleagues, 1990).
The design response: protect the N-terminus
If the N-terminal dipeptide is where the enzyme acts, the logical answer is to block that end. According to the product page, tesamorelin contains the complete 44-residue GHRH sequence with one addition: a trans-3-hexenoic acid group attached to the N-terminal tyrosine. That small acyl cap makes the peptide more resistant to cleavage by dipeptidyl peptidase IV. The calculated molecular weight is roughly 5.1 kDa, which makes it the largest GHRH analog in the V8 catalog.
The design principle generalizes. Peptide chemists have a short list of strategies for slowing enzymatic loss: swapping L- for D-amino acids, replacing the susceptible residue, capping the terminus, cyclizing, or attaching a lipid. Tesamorelin uses the terminal cap, which preserves the native sequence and so keeps its identity as a GHRH(1-44) analog. For a more detailed account of the chemistry, see the tesamorelin research overview; this page stays with the historical sequence.
| Approach | Example in this family | What it preserves | What it changes |
|---|---|---|---|
| Native sequence | GHRH(1-44) | Everything | Nothing; rapidly cleaved |
| Shortened sequence | GHRH(1-29)-type fragments such as sermorelin | The core receptor-binding region | Length; the N-terminus is still exposed |
| Substituted residues | Modified blends such as CJC-1295 without DAC | The fragment backbone | Several residues replaced to reduce cleavage |
| Terminal cap on full length | Tesamorelin | The full 44-residue sequence | A single acyl group at the N-terminus |
Comparisons with those other designs are set out in tesamorelin vs sermorelin and tesamorelin vs CJC-1295.
From laboratory molecule to a documented development program
The analog was subsequently carried through a development program, which Dhillon summarized in a review of its pharmacology and clinical evaluation (Dhillon, 2011). A laboratory reader does not need those clinical details to use this page, and none are reproduced here. The relevant point is historical: a molecule designed to solve an enzymology problem in a bench setting became a well-characterized reference analog, with a published literature on its pharmacology that research groups can draw on when choosing a stabilized, full-length GHRH ligand.
What the product is today
The tesamorelin product page lists a 10 mg vial of lyophilized powder, purity ≥98% by HPLC, formula C221H366N72O67S, classed as an N-terminally modified GHRH(1-44) analog. Storage is 2–8 °C, with −20 °C for long-term holding, protected from heat, moisture and light. The page describes uses in GHRH-receptor pharmacology with a stabilized full-length ligand, in adipose-tissue and lipid-metabolism research models, and in enzymatic-stability comparisons against native GHRH and shorter analogs. That last use is the one that most directly mirrors the history above: put native GHRH and the capped analog in the same medium with a source of dipeptidyl peptidase activity, sample over time and compare what remains by HPLC.
Bench notes for a historically informed experiment
- Use native GHRH as a comparator when stability is the question. Without it, resistance to cleavage is an assertion rather than a measurement.
- Time-course, not single time point. The enzyme story is kinetic; sample at several intervals.
- Allow longer dissolution for a larger peptide. At roughly 5 kDa it may need several minutes to clear; swirl, do not shake.
- Calculate concentration from the vial mass. c = m / V; moles from n = m / M with M near 5.1 kg/mol. The calculator handles the unit conversions.
- Check the lot against the certificate. Match the lot number to the COA library entry where published, and see tesamorelin purity testing for what the analytical data show.
- Store sensibly. Reconstitution and storage reasoning is in tesamorelin reconstitution and storage.
What the history does not tell you
The sources above establish that GHRH was isolated in 1982, that it is cleaved by dipeptidyl peptidase IV, that its receptor was cloned in 1992 and that a hexenoyl-capped analog was developed. They do not give a validated shelf life for reconstituted research-grade material, and they do not support any claim about a particular outcome in a particular model. Those questions need their own primary sources and their own controls. A plain-language introduction is available at what is tesamorelin, and sourcing considerations are in where to buy tesamorelin. Material is listed in the research catalog for laboratory research use only.
Related reading
- Tesamorelin research overview
- What is tesamorelin?
- Tesamorelin vs sermorelin
- Tesamorelin purity testing
- Where to buy tesamorelin for research
Frequently asked questions
Who discovered growth hormone-releasing hormone?
Growth hormone-releasing factor was isolated from a human pancreatic tumor and reported in 1982 by Guillemin and colleagues, with parallel characterization and sequence work by Rivier and colleagues and by Spiess and colleagues.
How many amino acids does native GHRH have?
Forty-four, with an amidated C-terminus. Tesamorelin keeps that full 44-residue sequence and adds one group at the N-terminus.
Why was native GHRH hard to use as a reagent?
It is cleaved quickly. Dipeptidyl peptidase IV removes the first two residues from the N-terminus, and the resulting peptide no longer activates the receptor effectively.
What is the hexenoyl group on tesamorelin?
A trans-3-hexenoic acid cap attached to the N-terminal tyrosine. The product page describes it as making the peptide more resistant to cleavage by dipeptidyl peptidase IV.
When was the GHRH receptor cloned?
Mayo reported the cloning and expression of a pituitary-specific GHRH receptor in 1992. It is a class B G protein-coupled receptor that signals through cyclic AMP.
How does tesamorelin differ from sermorelin?
Sermorelin is a shorter fragment of the GHRH sequence, while tesamorelin keeps the full 44 residues and protects the N-terminus with a hexenoyl cap.
What does the V8 tesamorelin vial contain?
A 10 mg lyophilized powder, purity ≥98% by HPLC, formula C221H366N72O67S, stored at 2–8 °C with −20 °C for long-term holding.
What is tesamorelin used for in the laboratory?
The product page lists GHRH-receptor pharmacology with a stabilized full-length ligand, adipose-tissue and lipid-metabolism research models, and enzymatic-stability comparisons with native GHRH.
How do I calculate the stock concentration?
Divide the vial mass by the diluent volume (c = m / V). Use the reconstitution calculator for unit conversions and record the figures with the lot number.
Is there a published shelf life for reconstituted tesamorelin?
Not for research-grade material. Keep solutions cold, limit time in solution, freeze single-use portions for longer holding and re-verify by HPLC if exact concentration matters.
Related reading: Tesamorelin Preclinical Studies: GH Response and Stability, Tesamorelin Quality Standards for Research Labs.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
- Spiess J, Rivier J, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982;21(24):6037-6040. doi:10.1021/bi00267a002
- Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. doi:10.1172/jci114049
- Frohman LA, Downs TR, Chomczynski P, Frohman MA. Growth hormone-releasing hormone: structure, gene expression and molecular heterogeneity. Acta Paediatr Scand Suppl. 1990;367:81-86. doi:10.1111/j.1651-2227.1990.tb11639.x
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
- Dhillon S. Tesamorelin. Drugs. 2011;71(8):1071-1091. doi:10.2165/11202240-000000000-00000
